BRENDA - Enzyme Database

A lipid binding domain in sphingosine kinase 2

Don, A.S.; Rosen, H.; Biochem. Biophys. Res. Commun. 380, 87-92 (2009)

Data extracted from this reference:

Activating Compound
EC Number
Activating Compound
Commentary
Organism
Structure
2.7.1.91
cholesterol
0.01 mM, isoform SphK2, 107% of initial activity
Homo sapiens
2.7.1.91
galactosylceramide
0.01 mM, isoform SphK2, 84% of initial activity, isoform SphK1, 109% of initial activity
Homo sapiens
2.7.1.91
galactosylceramide 3-sulfate
0.01 mM, isoform SphK2, 37% of initial activity, isoform SphK1, 156% of initial activity
Homo sapiens
2.7.1.91
phosphatidic acid
0.01 mM, isoform SphK2, 102% of initial activity, isoform SphK1, 265% of initial activity
Homo sapiens
2.7.1.91
phosphatidylinositol
0.01 mM, isoform SphK2,187% of initial activity
Homo sapiens
2.7.1.91
phosphatidylinositol 4-phosphate
0.01 mM, isoform SphK2, 89% of initial activity, isoform SphK1, 175% of initial activity
Homo sapiens
2.7.1.91
phosphatidylserine
0.01 mM, isoform SphK2, 203% of initial activity
Homo sapiens
Cloned(Commentary)
EC Number
Commentary
Organism
2.7.1.91
-
Homo sapiens
Engineering
EC Number
Amino acid exchange
Commentary
Organism
2.7.1.91
additional information
isoform SphK2 contains a lipid binding domain at the N-terminal residues 1-175, a region of sequence that is absent in Sphk1. Deleting the N-terminal domain reduces Sphk2 membrane localisation in cells
Homo sapiens
Inhibitors
EC Number
Inhibitors
Commentary
Organism
Structure
2.7.1.91
3-O-sulfogalactosylceramide
endogenous glycolipid sulfatide, binds to and inhibits the activity of isoform Sphk2 and the closely related ceramide kinase Cerk, but not isoform Sphk1. The lipid binding domain is mapped to the N-terminus of Sphk2, residues 1-175, a region of sequence that is absent in Sphk1, but aligns with a pleckstrin homology domain in Cerk
Homo sapiens
2.7.1.91
galactosylceramide
0.01 mM, isoform SphK2, 84% of initial activity, isoform SphK1, 109% of initial activity
Homo sapiens
2.7.1.91
galactosylceramide 3-sulphate
0.01 mM, isoform SphK2, 37% of initial activity, isoform SphK1, 156% of initial activity
Homo sapiens
2.7.1.91
additional information
isoform Sphk2 binds to phosphatidylinositol monophosphates but not to abundant cellular phospholipids
Homo sapiens
2.7.1.91
phosphatidylinositol 4,5-bisphosphate
0.01 mM, isoform SphK2, 60% of initial activity, isoform SphK1, 90% of initial activity
Homo sapiens
2.7.1.91
phosphatidylinositol 4-phosphate
0.01 mM, isoform SphK2, 89% of initial activity, isoform SphK1, 175% of initial activity
Homo sapiens
KM Value [mM]
EC Number
KM Value [mM]
KM Value Maximum [mM]
Substrate
Commentary
Organism
Structure
2.7.1.91
1
-
nitrobenzoxadiazole-labeled sphingosine
pH 7.4, 35°C, presence of 10 microM 3-O-sulfogalactosylceramide
Homo sapiens
2.7.1.91
1.7
-
nitrobenzoxadiazole-labeled sphingosine
pH 7.4, 35°C; pH 7.4, 35°C, presence of 25 microM 3-O-sulfogalactosylceramide
Homo sapiens
2.7.1.91
3.6
-
nitrobenzoxadiazole-labeled sphingosine
pH 7.4, 35°C, presence of 4 microM 3-O-sulfogalactosylceramide
Homo sapiens
Localization
EC Number
Localization
Commentary
Organism
GeneOntology No.
Textmining
2.7.1.91
membrane
deleting the N-terminal domain with residues 1-175 reduces Sphk2 membrane localisation in cells
Homo sapiens
16020
-
Organism
EC Number
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
2.7.1.91
Homo sapiens
-
-
-
Substrates and Products (Substrate)
EC Number
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
2.7.1.91
ATP + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
-
702037
Homo sapiens
ADP + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine 1-phosphate
-
-
-
?
Activating Compound (protein specific)
EC Number
Activating Compound
Commentary
Organism
Structure
2.7.1.91
cholesterol
0.01 mM, isoform SphK2, 107% of initial activity
Homo sapiens
2.7.1.91
galactosylceramide
0.01 mM, isoform SphK2, 84% of initial activity, isoform SphK1, 109% of initial activity
Homo sapiens
2.7.1.91
galactosylceramide 3-sulfate
0.01 mM, isoform SphK2, 37% of initial activity, isoform SphK1, 156% of initial activity
Homo sapiens
2.7.1.91
phosphatidic acid
0.01 mM, isoform SphK2, 102% of initial activity, isoform SphK1, 265% of initial activity
Homo sapiens
2.7.1.91
phosphatidylinositol
0.01 mM, isoform SphK2,187% of initial activity
Homo sapiens
2.7.1.91
phosphatidylinositol 4-phosphate
0.01 mM, isoform SphK2, 89% of initial activity, isoform SphK1, 175% of initial activity
Homo sapiens
2.7.1.91
phosphatidylserine
0.01 mM, isoform SphK2, 203% of initial activity
Homo sapiens
Cloned(Commentary) (protein specific)
EC Number
Commentary
Organism
2.7.1.91
-
Homo sapiens
Engineering (protein specific)
EC Number
Amino acid exchange
Commentary
Organism
2.7.1.91
additional information
isoform SphK2 contains a lipid binding domain at the N-terminal residues 1-175, a region of sequence that is absent in Sphk1. Deleting the N-terminal domain reduces Sphk2 membrane localisation in cells
Homo sapiens
Inhibitors (protein specific)
EC Number
Inhibitors
Commentary
Organism
Structure
2.7.1.91
3-O-sulfogalactosylceramide
endogenous glycolipid sulfatide, binds to and inhibits the activity of isoform Sphk2 and the closely related ceramide kinase Cerk, but not isoform Sphk1. The lipid binding domain is mapped to the N-terminus of Sphk2, residues 1-175, a region of sequence that is absent in Sphk1, but aligns with a pleckstrin homology domain in Cerk
Homo sapiens
2.7.1.91
galactosylceramide
0.01 mM, isoform SphK2, 84% of initial activity, isoform SphK1, 109% of initial activity
Homo sapiens
2.7.1.91
galactosylceramide 3-sulphate
0.01 mM, isoform SphK2, 37% of initial activity, isoform SphK1, 156% of initial activity
Homo sapiens
2.7.1.91
additional information
isoform Sphk2 binds to phosphatidylinositol monophosphates but not to abundant cellular phospholipids
Homo sapiens
2.7.1.91
phosphatidylinositol 4,5-bisphosphate
0.01 mM, isoform SphK2, 60% of initial activity, isoform SphK1, 90% of initial activity
Homo sapiens
2.7.1.91
phosphatidylinositol 4-phosphate
0.01 mM, isoform SphK2, 89% of initial activity, isoform SphK1, 175% of initial activity
Homo sapiens
KM Value [mM] (protein specific)
EC Number
KM Value [mM]
KM Value Maximum [mM]
Substrate
Commentary
Organism
Structure
2.7.1.91
1
-
nitrobenzoxadiazole-labeled sphingosine
pH 7.4, 35°C, presence of 10 microM 3-O-sulfogalactosylceramide
Homo sapiens
2.7.1.91
1.7
-
nitrobenzoxadiazole-labeled sphingosine
pH 7.4, 35°C; pH 7.4, 35°C, presence of 25 microM 3-O-sulfogalactosylceramide
Homo sapiens
2.7.1.91
3.6
-
nitrobenzoxadiazole-labeled sphingosine
pH 7.4, 35°C, presence of 4 microM 3-O-sulfogalactosylceramide
Homo sapiens
Localization (protein specific)
EC Number
Localization
Commentary
Organism
GeneOntology No.
Textmining
2.7.1.91
membrane
deleting the N-terminal domain with residues 1-175 reduces Sphk2 membrane localisation in cells
Homo sapiens
16020
-
Substrates and Products (Substrate) (protein specific)
EC Number
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
2.7.1.91
ATP + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
-
702037
Homo sapiens
ADP + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine 1-phosphate
-
-
-
?